News

Filter

Current filters:

Astellas PharmaOncology

1 to 9 of 81 results

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

Qiagen signs agreement with Astellas Pharma to develop companion diagnostics

Qiagen signs agreement with Astellas Pharma to develop companion diagnostics

29-10-2014

Netherlands-based company Qiagen has announced a master collaboration agreement with Japanese drug major…

Astellas PharmaJapanLicensingNetherlandsOncologyPharmaceuticalQiagen

FDA grants approval for Xtandi in metastatic prostate cancer

FDA grants approval for Xtandi in metastatic prostate cancer

01-10-2014

Japanese drug major Astellas Pharma and Medivation has received extended approval for Xtandi (enzalutamide)…

Astellas PharmaDiplomatMedivationOncologyPharmaceuticalRegulationUSAXtandi

New indication for Astellas/Medivation’s Xtandi from US FDA

New indication for Astellas/Medivation’s Xtandi from US FDA

11-09-2014

The US Food and Drug Administration has approved a new indication for the use of Japanese drug major…

Astellas PharmaMedivationOncologyPharmaceuticalResearchUSAXtandi

Astellas' isavuconazole NDA accepted by US FDA

Astellas' isavuconazole NDA accepted by US FDA

08-09-2014

The US Food and Drug Administration has accepted a New Drug Application filing by Japanese drug major…

Astellas PharmaFungal diseasesInvasive aspergillosisInvasive mucormycosisisavuconazoleOncologyPharmaceuticalRegulationUSA

Cancer Research UK and Astellas join forces on pancreatic cancer treatment

09-08-2014

Japanese drug major Astellas Pharma is joining forces with Cancer Research UK and its commercial arm,…

Astellas PharmaCancer Research TechnologyLicensingOncologyPharmaceuticalResearch

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

UK’s NICE recommends Xtandi and Yervoy under patient access schemes

23-07-2014

The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance recommending…

Astellas PharmaBristol-Myers SquibbOncologyPharmaceuticalRegulationUKXtandiYervoy

Astellas details pipeline progress at R&D meeting

Astellas details pipeline progress at R&D meeting

11-07-2014

Japanese drug major Astellas Pharmaceuticals outlined its research framework at its R&D meeting held…

Anti-Arthritics/RheumaticsAntibiotics and Infectious diseasesAstellas PharmaBetmigaisavuconazoleJapanNephrology and HepatologyOncologyPharmaceuticalroxadustatXtandi

1 to 9 of 81 results

COMPANY SPOTLIGHT

Menarini

Back to top